GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,559.00GBp
17 Apr 2014
Price Change (% chg)

-4.50p (-0.29%)
Prev Close
1,563.50p
Open
1,557.00p
Day's High
1,560.00p
Day's Low
1,545.00p
Volume
9,786,769
Avg. Vol
7,682,909
52-wk High
1,816.00p
52-wk Low
1,528.00p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.48
Market Cap (Mil.): £75,779.24
Shares Outstanding (Mil.): 4,859.29
Dividend: 23.00
Yield (%): 5.00

Financials

  GSK.L Industry Sector
P/E (TTM): 14.03 33.26 33.35
EPS (TTM): 1.11 -- --
ROI: 20.72 19.66 18.92
ROE: 84.96 20.35 19.68
Search Stocks

AbbVie urges U.S. court to avoid gay rights issue in HIV drug case

- An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians.

18 Apr 2014

AbbVie urges U.S. court to avoid gay rights issue in HIV drug case

April 18 - An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians.

18 Apr 2014

BRIEF-GSK gets Canadian approval for bronchodilator treatment Incruse

* Glaxosmithkline plc gsk receives approval in Canada for incruse

17 Apr 2014

GSK, facing bribery claims, battles to build new sales model

LONDON - Drugmaker GlaxoSmithKline - hit by bribery claims in five countries - is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices.

17 Apr 2014

GSK, facing bribery claims, battles to build new sales model

* GSK hopes for long-term competitive advantage with revamp

17 Apr 2014

Galapagos, GSK successfully conclude phase 2a study of skin disease drug

BRUSSELS - Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC.

17 Apr 2014

Galapagos, GSK successfully conclude phase 2a study of skin disease drug

BRUSSELS, April 17 - Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC.

17 Apr 2014

UPDATE 1-GSK says investigating claims of bribery in Jordan, Lebanon

* Follows earlier claims of bribes in China, Poland, Iraq (Adds details on allegations, further GSK comment)

16 Apr 2014

GSK says investigating claims of bribery in Jordan, Lebanon

LONDON, April 16 - Drugmaker GlaxoSmithKline said on Wednesday it was investigating allegations of bribery involving some of its staff in Jordan and Lebanon, following earlier claims of corruption in China, Iraq and Poland.

16 Apr 2014

FDA approves GSK's Tanzeum to treat type 2 diabetes

- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise.

15 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks